All stocks today
71229 stocks real-time data.
All stocks today

Stock quotes

Stock market live

Historical stock prices

Stocks market capitalization

Dividend stocks

Stock earnings

Stock revenue

Stock ratings. Where to invest?

Intra-Cellular Therapies, Inc. revenue reports

Intra-Cellular Therapies, Inc. financial reports, Intra-Cellular Therapies, Inc. annual revenue in 2020. When does Intra-Cellular Therapies, Inc. report revenue?
Add to widgets
Added to widgets

Intra-Cellular Therapies, Inc. total revenue, net income and dynamics of changes in US dollar today

Intra-Cellular Therapies, Inc. current income and income for the latest reporting periods. Net income Intra-Cellular Therapies, Inc. - -34 862 399 $. Information about net income is used from open sources. Net income, revenue and dynamics - the main financial indicators of Intra-Cellular Therapies, Inc.. Schedule of the financial report of Intra-Cellular Therapies, Inc. for today. The financial schedule of Intra-Cellular Therapies, Inc. consists of three charts of the main financial indicators of the company: total assets, net revenue, net income. Information on Intra-Cellular Therapies, Inc. net income on the chart on this page is drawn in blue bars.

Report date Total revenue
Total revenue refers to the total receipts from sales of a given quantity of goods or services. It is the total income of a business and is calculated by multiplying the quantity of goods sold by the price of the goods.
and Change (%)
Comparing current quartal report this year to quartal report last year.
Net income
Net income is an entity's income minus cost of goods sold, expenses and taxes for an accounting period.
and Change (%)
Comparing current quartal report this year to quartal report last year.
30/09/2019 0 $ - -34 862 399 $ -
30/06/2019 0 $ - -37 441 164 $ -
31/03/2019 0 $ - -34 835 763 $ -
31/12/2018 0 $ -100 % ↓ -40 748 036 $ -
30/09/2018 0 $ - -41 522 914 $ -
30/06/2018 0 $ - -37 376 383 $ -
31/03/2018 0 $ - -35 480 078 $ -
31/12/2017 5 055 $ - -30 208 712 $ -
30/09/2017 30 754 $ - -22 870 416 $ -
30/06/2017 114 741 $ - -17 760 704 $ -
Show:
to

Intra-Cellular Therapies, Inc. financial report charts

The dates of the latest financial statements of Intra-Cellular Therapies, Inc.: 30/06/2017, 30/06/2019, 30/09/2019. The dates of financial statements are strictly regulated by law and financial statements. The latest financial report of Intra-Cellular Therapies, Inc. is available online for such a date - 30/09/2019. Gross profit Intra-Cellular Therapies, Inc. is the profit a company makes after deducting the costs of making and selling its products, or the costs of providing its services. Gross profit Intra-Cellular Therapies, Inc. is -21 339 792 $

Intra-Cellular Therapies, Inc. quarterly report dates

Cost of revenue Intra-Cellular Therapies, Inc. is the total cost of producing and distributing of products and services of a company. Cost of revenue Intra-Cellular Therapies, Inc. is 21 339 792 $ Operating income Intra-Cellular Therapies, Inc. is an accounting figure that measures the amount of profit realized from a business's operations, after deducting operating expenses such as wages, depreciation and cost of goods sold (COGS). Operating income Intra-Cellular Therapies, Inc. is -36 376 236 $ Net income Intra-Cellular Therapies, Inc. is an entity's income minus cost of goods sold, expenses and taxes for an accounting period. Net income Intra-Cellular Therapies, Inc. is -34 862 399 $

Current assets Intra-Cellular Therapies, Inc. is a balance sheet item that represents the value of all assets that can reasonably expect to be converted into cash within one year. Current assets Intra-Cellular Therapies, Inc. is 259 456 926 $ Total assets Intra-Cellular Therapies, Inc. refers to the total amount of assets owned by a person or entity. Total assets Intra-Cellular Therapies, Inc. is 280 523 030 $ Current cash Intra-Cellular Therapies, Inc. - the sum of all of the cash a company has on the date of report. Current cash Intra-Cellular Therapies, Inc. is 102 162 982 $

30/09/2019 30/06/2019 31/03/2019 31/12/2018 30/09/2018 30/06/2018 31/03/2018 31/12/2017 30/09/2017 30/06/2017
Gross profit
Gross profit is the profit a company makes after deducting the costs of making and selling its products, or the costs of providing its services.
-21 339 792 $ -23 728 464 $ -24 990 856 $ -33 605 629 $ -35 419 016 $ -32 439 270 $ - - - -
Cost of revenue
Cost of revenue is the total cost of producing and distributing of products and services of a company.
21 339 792 $ 23 728 464 $ 24 990 856 $ 33 605 629 $ 35 419 016 $ 32 439 270 $ - - - -
Total revenue
Total revenue refers to the total receipts from sales of a given quantity of goods or services. It is the total income of a business and is calculated by multiplying the quantity of goods sold by the price of the goods.
- - - - - - - 5 055 $ 30 754 $ 114 741 $
Operating revenue
Operating revenue is revenue generated from a company's primary business activities. For example, a retailer produces revenue through merchandise sales, and a physician derives revenue from the medical services he/she provides.
- - - - - - - 5 055 $ 30 754 $ 114 741 $
Operating income
Operating income is an accounting figure that measures the amount of profit realized from a business's operations, after deducting operating expenses such as wages, depreciation and cost of goods sold (COGS).
-36 376 236 $ -39 171 114 $ -36 695 840 $ -42 622 940 $ -43 391 345 $ -39 168 257 $ -37 084 226 $ -32 708 264 $ -23 759 195 $ -18 618 513 $
Net income
Net income is an entity's income minus cost of goods sold, expenses and taxes for an accounting period.
-34 862 399 $ -37 441 164 $ -34 835 763 $ -40 748 036 $ -41 522 914 $ -37 376 383 $ -35 480 078 $ -30 208 712 $ -22 870 416 $ -17 760 704 $
R&D spending
Research and Development spending - cost of investigative activities to improve existing products and procedures or to lead to the development of new products and procedures.
- - - - - - 30 702 998 $ 26 929 041 $ 18 472 372 $ 12 478 638 $
Operating expense
An operating expense is an expenditure that a business incurs as a result of performing its normal business operations.
36 376 236 $ 39 171 114 $ 36 695 840 $ 42 622 940 $ 43 391 345 $ 39 168 257 $ 37 084 226 $ 32 713 319 $ 23 789 949 $ 18 733 254 $
Current assets
Current assets is a balance sheet item that represents the value of all assets that can reasonably expect to be converted into cash within one year.
259 456 926 $ 288 341 898 $ 321 127 630 $ 355 438 681 $ 383 253 450 $ 409 661 068 $ 443 153 579 $ 469 215 328 $ 333 435 470 $ 348 834 869 $
Total assets
Total assets refers to the total amount of assets owned by a person or entity.
280 523 030 $ 309 862 614 $ 342 972 817 $ 357 206 498 $ 385 587 198 $ 412 073 723 $ 445 639 072 $ 471 486 699 $ 334 190 841 $ 349 539 535 $
Current cash
Current cash - the sum of all of the cash a company has on the date of report.
102 162 982 $ 91 763 368 $ 64 091 080 $ 54 947 502 $ 69 776 956 $ 69 767 045 $ 74 421 386 $ 37 790 114 $ 52 340 519 $ 29 590 446 $
Current debt
Current debt is the portion of debt due within a year (12 months) and is listed as a current liability and part of net working capital.
33 373 099 $ 32 526 487 $ 33 499 301 $ 36 299 185 $ 29 128 896 $ 18 935 367 $ - - - -
Total cash
Total cash - the sum of all of the cash a company has on its books, including petty cash and funds on deposit in a bank.
- - - - - - 437 005 512 $ 464 331 035 $ 328 121 804 $ 342 628 115 $
Total debt
Total debt is a combination of both short-term and long-term debt. Short-term debts are those that must be paid back within a year. Long-term debt generally includes every liability that must be paid off in more than a year.
53 642 745 $ 53 094 252 $ 54 358 390 $ 39 491 617 $ 31 961 802 $ 21 686 281 $ - - - -
Debt ratio
Total debt to total assets - is a financial ratio that indicates the percentage of a company's assets that are provided via debt.
19.12 % 17.13 % 15.85 % 11.06 % 8.29 % 5.26 % - - - -
Shareholders equity
Shareholder's equity (SE) is the owner's claim after subtracting total liabilities from total assets.
226 880 285 $ 256 768 362 $ 288 614 427 $ 317 714 881 $ 353 625 396 $ 390 387 442 $ 423 188 955 $ 454 436 961 $ 319 440 076 $ 339 665 724 $
Cash flow
Cash flow is the net amount of cash and cash-equivalents being transferred into and out of a business.
-29 989 290 $ -27 308 710 $ -35 629 325 $ -29 161 536 $ -28 409 537 $ -33 614 041 $ -26 983 999 $ -24 792 734 $ -14 412 227 $ -24 888 290 $

Last revenue report of Intra-Cellular Therapies, Inc. was 30/09/2019. According to last financial report total revenue in Intra-Cellular Therapies, Inc. was 0 US dollar and changed by -100% since last year. Net income in Intra-Cellular Therapies, Inc. was -34 862 399 $ in last quartal, net income changes to 0%.

Current debt Intra-Cellular Therapies, Inc. is the portion of debt due within a year (12 months) and is listed as a current liability and part of net working capital. Current debt Intra-Cellular Therapies, Inc. is 33 373 099 $ Total debt Intra-Cellular Therapies, Inc. is a combination of both short-term and long-term debt. Short-term debts are those that must be paid back within a year. Long-term debt generally includes every liability that must be paid off in more than a year. Total debt Intra-Cellular Therapies, Inc. is 53 642 745 $ Cash flow Intra-Cellular Therapies, Inc. is the net amount of cash and cash-equivalents being transferred into and out of a business. Cash flow Intra-Cellular Therapies, Inc. is -29 989 290 $

Intra-Cellular Therapies, Inc. stocks data

Intra-Cellular Therapies, Inc. financials